https://www.selleckchem.com/pr....oducts/5-chloro-2-de
of men had low- and intermediate-risk disease. Longer follow-up is needed. At a median follow-up point of 10 years, prostate cancer-specific mortality was low, irrespective of the assigned treatment. Radical prostatectomy and radical radiotherapy reduced disease progression and metastases, but with side effects. Further work is needed to follow up participants at a median of 15 years. Current Controlled Trials ISRCTN20141297. This project was funded by the National Institute for Health Research Health Technology Assessme
Like
Comment
Share
